FDA approves injectable drug to treat opioid-dependent patients

The U.S. Food and Drug Administration today approved Vivitrol
to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.
Vivitrol is an extended-release formulation of naltrexone administered by intramuscular injection once a month.
Naltrexone works to block opioid receptors in the brain. It blocks the effects of drugs like morphine, heroin, and other opioids.
It was approved to treat alcohol dependence in 2006. To view the FDA press release in its entirety, click
here

Tagged as: buprenorphine, buprenorphine research, information, suboxone, suboxone research